GLP-1 Agonists for Obesity
Expert Insights on GLP-1: Transforming Obesity & Diabetes Management
Join us for a special Stanford Med Matters YouTube premiere featuring experts in obesity treatment and GLP-1 receptor agonist therapies. Hosted by a distinguished panel of clinicians, this episode explores the history, current guidelines, and groundbreaking future of GLP-1 treatments for pediatric and adult populations. Gain valuable insights into how GLP-1 therapies have transformed the landscape of obesity management and patient outcomes, and hear exclusive recommendations for clinicians treating obesity as a complex metabolic disease. Don’t miss this opportunity—subscribe to the Stanford CME channel and set your reminders for the premiere now!
Breakthrough Study by SDRC Investigator Jonathan Long Uncovers the Connection Between PTER and Taurine Metabolism in the Fight Against Obesity
Jonathan Long's team has uncovered a link between PTER and taurine metabolism in mice, revealing its potential to combat weight gain and metabolic disorders thus paving the way for innovative anti-obesity drugs through a novel GLP1R-independent pathway.
Jonathan Long's team has uncovered a link between PTER and taurine metabolism in mice, revealing its potential to combat weight gain and metabolic disorders thus paving the way for innovative anti-obesity drugs through a novel GLP1R-independent pathway.
Thomas Robinson leads Stanford Medicine Study: Healthy Eating and Activity Boost Telomere Length in Kids with Obesity
Telomere length could serve as an effective indicator for assessing the benefits of healthy diet changes, physical activity, and weight management.
Telomere length could serve as an effective indicator for assessing the benefits of healthy diet changes, physical activity, and weight management.